Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CAPSAPED: Capsaicin 8% Patch in Pediatric Neuropathic Pain
2022-500265-27-00Phase 3Authorised
- Sponsor
- Centre Hospitalier Universitaire de Brest
- Start
- Jul 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in Neuralgia comparing Qutenza 8% capsaicin patch with Placebo hydrocolloid dressing (2 arms). Primary endpoint: Change in NPSI total score at 4 months. Planned start Jul 2023; status: authorised.
02
Drugs
capsaicin
03
Conditions
Neuralgia
Beyond the preview
Go deeper on 2022-500265-27-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2022-500265-27-00.